175 INNOVATION BOULEVARD, WILMINGTON, DE
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Announces Pricing of $90.0 Million Underwritten Offering
Investor Presentation
Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload